Thank you to our Foundational and Sustaining members
The pandemic pushed medtech to move faster, and leaders are riding that influence to discover sustainable efficiencies throughout the organization. Learn from two medtech experts on how they are enacting long-lasting change in their organizations. There is always a demand for medical innovations to be delivered faster, but the COVID-19 pandemic accelerated trials to a […]
Collaboration will yield objective, predictive, and real-time digital measures—supplementing clinical trial digital endpoints collected from biosensors. RESEARCH TRIANGLE PARK, N.C., and CHICAGO, February 3rd, 2022 — Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, and physIQ Inc, a leader in digital medicine, today announced a collaboration to help research sponsors use […]
MAPLE GROVE, Minn. (Nov. 9, 2021) – HLT Inc., a Bracco Group Company, leading the development of cutting edge transcatheter aortic valve replacement (TAVR) therapy, has named Dr. Satya Shreenivas as its new chief medical officer. Dr. Shreenivas was most recently one of the primary structural heart physicians at The Christ Hospital and prior to that […]
As the pandemic winds down, clinical trials, product development and product commercialization are once again ramping up. That means more innovative pharmaceuticals, medical devices, software programs, biologics and other life-altering therapies will soon be more readily available to those who need them. That positive news also carries the potential for a variety of significant risks. […]
Prior to launching Talencio in January 2008, I had a successful career as an accounting executive for several medical device companies. I played a key role in successful liquidity events and raised $200M in financing. Building on my experience within the health technology sector, Talencio is the expression of my real passion: helping others succeed. […]
MINNEAPOLIS (June 9, 2020) – Francis Medical, Inc., a Minneapolis-based, privately held medical device company developing an innovative and proprietary water vapor ablation therapy for the treatment of prostate, kidney, and bladder cancer, announced the enrollment of their first patient in the company’s VAPOR 1 clinical study. VAPOR 1 is an early feasibility study evaluating the safety […]
Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial for RBX2660 RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridiodes difficile (C. diff) infection recurrences CDC defines C. diff as a major burden to patients and doctors and an urgent […]
Via Francis Medical “Like most companies, Francis Medical is facing several unique challenges brought on by the coronavirus pandemic. However, unlike many companies facing the prospect of lost revenues, the real enemy of a pre-revenue startup company, like Francis Medical, is lost time. ‘Every day of delay to our timeline could mean one day later […]
Prism Clinical Research (a Nucleus Network company) is playing a key role in supporting the University of Minnesota as it commences trialling a COVID-19 prevention treatment targeting frontline healthcare workers and first responders. David Boulware, MD, MPH, a professor in the University of Minnesota Medical School’s Department of Medicine in the Division of Infectious Diseases […]
Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis […]